Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

Ghana on Tuesday unveiled a National Sickle Cell Disease (SCD) Strategy aimed at improving both preventive and treatment services for the condition.

MGM Medical College in Indore will inaugurate a cutting-edge molecular lab for the early detection of sickle cell anaemia on November 15, enhancing diagnosis and treatment options for patients, ...

This case study is an example of how the MHRA is benefiting from patients providing their lived experience for the pre-authorisation stage of the ...

Ghana on Tuesday unveiled a National Sickle Cell Disease (SCD) Strategy aimed at improving both preventive and treatment services for the condition.

Because the eyes can potentially reveal signals about conditions like diabetes, heart disease, kidney disease, sickle cell ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease ... a lifelong ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...